Advertisement

What is the Current Knowledge about the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review

  • E. Jouanjus
    Affiliations
    Centre d’Evaluation et d’Information sur la Pharmacodépendance (CEIP)–Addictovigilance, Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire, Toulouse, France

    Inserm UMR 1027, Equipe de Pharmacoépidémiologie, Université Toulouse III, Toulouse, France
    Search for articles by this author
  • V. Raymond
    Affiliations
    Inserm UMR 1027, Equipe de Pharmacoépidémiologie, Université Toulouse III, Toulouse, France
    Search for articles by this author
  • M. Lapeyre-Mestre
    Affiliations
    Centre d’Evaluation et d’Information sur la Pharmacodépendance (CEIP)–Addictovigilance, Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire, Toulouse, France

    Inserm UMR 1027, Equipe de Pharmacoépidémiologie, Université Toulouse III, Toulouse, France
    Search for articles by this author
  • V. Wolff
    Affiliations
    Unité neuro-vasculaire, Centre Hospitalier Régional Universitaire, Strasbourg, France
    Search for articles by this author
      As emphasized by the World Health Organization (WHO), cannabis use represents a risky behavior as it may lead to many adverse effects, and in particular, cardiovascular effects. The objective was to examine the published evidence on the cardiovascular risk related to the use of cannabis-based products, by performing a systematic review of recent literature.
      To read this article in full you will need to make a payment
      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect